[Association between periconceptional folic acid supplementation and small for gestational age birth based on

L L Guo1, J X Shen1, S H Ru1

  • 1Department of Epidemiology, School of Public Health.

Insights

Periconceptional folic acid supplementation, particularly 400 μg, may reduce the risk of small for gestational age (SGA) birth in overweight pregnant women. Maternal pre-pregnancy body mass index (BMI) appears to influence this protective effect.

Area of Science:

  • Obstetrics and Gynecology
  • Maternal-Fetal Medicine
  • Nutritional Epidemiology

Background:

  • Small for gestational age (SGA) birth is a significant concern in perinatal health.
  • Maternal pre-pregnancy body mass index (BMI) is a known factor influencing pregnancy outcomes.
  • The role of periconceptional folic acid supplementation in SGA prevention requires further elucidation, especially concerning maternal BMI.

Purpose of the Study:

  • To investigate the association between periconceptional folic acid supplementation and SGA birth.
  • To examine how maternal pre-pregnancy BMI modifies the relationship between folic acid intake and SGA risk.
  • To inform the development of targeted SGA prevention strategies.

Main Methods:

  • A cohort study involving 8,523 pregnant women delivering between March 2012 and September 2016.
  • Data collected on demographics, folic acid supplementation, and infant outcomes (SGA vs. appropriate for gestational age).
  • Unconditional logistic regression analysis, with stratification by pre-pregnancy BMI, was employed to assess associations.

Main Results:

  • The overall incidence of SGA birth was 12.51%.
  • Periconceptional folic acid supplementation (400 μg) was associated with a reduced risk of SGA (OR=0.82).
  • This protective effect was significant in overweight women (24.0 kg/m² ≤ BMI < 28.0 kg/m²), with OR=0.55 for single folic acid supplementation.

Conclusions:

  • Periconceptional folic acid supplementation (400 μg) is linked to a lower risk of SGA birth, particularly in women with pre-pregnancy BMI between 24.0 and 28.0 kg/m².
  • No significant association was found in other BMI categories.
  • Maternal pre-pregnancy BMI may modify the effectiveness of folic acid supplementation in preventing SGA births.

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.3K
Regression Toward the Mean01:52

Regression Toward the Mean

Regression toward the mean (“RTM”) is a phenomenon in which extremely high or low values—for example, and individual’s blood pressure at a particular moment—appear closer to a group’s average upon remeasuring. Although this statistical peculiarity is the result of random error and chance, it has been problematic across various medical, scientific, financial and psychological applications. In particular, RTM, if not taken into account, can interfere when...
7.2K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
303